Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 11/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485577 | 0.94 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1065984 | 0.92 | MAPK14 (0.41) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1065169 | 0.90 | MAPK14 (0.36) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4181561 | 0.90 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4463596 | 0.88 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1065121 | 0.86 | MAPK14 (0.37) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4470368 | 0.85 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1059157 | 0.82 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL14201929 | 0.81 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1065956 | 0.81 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137550-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-05-28 | — | — | US | disclosed |
| US-20090137550-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-05-28 | — | — | US | disclosed |
| US-20090137550-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-05-28 | — | — | US | disclosed |
| US-20090005401-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-01-01 | — | — | US | disclosed |
| US-20090005401-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-01-01 | — | — | US | disclosed |
| US-20090005401-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-01-01 | — | — | US | disclosed |
| US-7423042-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
| US-7423042-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
| US-7423042-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
| EP-1868612-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006110298-A2 | 8-ALKYL/ARYL-4-ARYL-2-N- (ALKYLAMINO)-N'-SUBSTITUTED-N'-CYANOGUANIDINO-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND USE THEREOF | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| US-20060217401-A1 | e.g. 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N''-substituted-N'-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds; CSBP/p38 kinase inhibitor; antiinflammatory agent; inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, rheumatoid arthritis | GLAXO GROUP LIMITED (GB) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217401-A1 | e.g. 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N''-substituted-N'-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds; CSBP/p38 kinase inhibitor; antiinflammatory agent; inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, rheumatoid arthritis | MAPK8, MAPKAPK2, MAPK7 | MAPK14 14/4885MAPK13 19/4885MAPK12 37/4885 |
| US-20090005401-A1 | Novel Compounds | MAPKAPK2, CREBBP, MAPK8 | MAPK14 53/4885MAPK13 51/4885MAPK12 39/4885 |
| US-20090137550-A1 | Novel Compounds | MAPKAPK2, CREBBP, MAPK8 | MAPK14 53/4885MAPK13 51/4885MAPK12 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.